Portal de Periódicos da CAPES

Dupilumab treatment in paediatric atopic dermatitis (2 to 18 years): Spanish multicentre retrospective real-life study

2024; Oxford University Press; Linguagem: Inglês

10.1093/ced/llae300

1365-2230

Helena Iznardo, Esther Roé, Asunción Vicente, Carolina Prat, Miquel Ninyerola i Casals, A. Martín‐Santiago, Altea Esteve, Miguel Viñas, M. Munera‐Campos, Francesca Corella, Jordi Mollet, Ignasi Figueras‐Nart, A. Martin Vila, X. Soria, A Azón, Laura Marqués-Martín, Cristina Nadal‐Lladó, Susana Bel, Josep Pujol‐Montcusí, Marta Bertolín‐Colilla, Laia Curto‐Barredo, Gemma Melé‐Ninot, M. Évole, L. Berbegal, L. Puig, Eulàlia Baselga,

Food Allergy and Anaphylaxis Research

Moderate-to-severe atopic dermatitis (AD) can be difficult to manage in paediatric patients, with few licensed treatments in this age group. Dupilumab is approved for AD in children older than 6 months.